APONTIS PHARMA AG |
Market Closed -
Other stock markets
|
After market 12:19:25 am | |||
| 8.5 EUR | -0.47% |
|
8.49 | -0.12% |
| 05/04 | Apontis Bags Distribution Deal with Novartis Unit for Two Asthma Medications | MT |
| 28/03 | Apontis Pharma AG Reports Earnings Results for the Full Year Ended December 31, 2023 | CI |
Business Summary
Number of employees: 177
Sales per Business
| EUR in Million | 2022 | Weight | 2023 | Weight | Delta |
|---|---|---|---|---|---|
Single Pills - Hypertension
69.4
%
| 37 | 65.6 % | 26 | 69.4 % | -29.84% |
Co-Marketing - CO PD (Respiratory Diseases)
21.5
%
| 10 | 17.9 % | 8 | 21.5 % | -20.21% |
Corporate Brands (without Single Pills) - Other
5.6
%
| 2 | 3.8 % | 2 | 5.6 % | -3.07% |
Co-Marketing - Cardiovascular
3.1
%
| - | - | 1 | 3.1 % | - |
Co-Marketing - Diabetes
0.5
%
| 7 | 12.3 % | 0 | 0.5 % | -97.44% |
Sales per region
| EUR in Million | 2022 | Weight | 2023 | Weight | Delta |
|---|---|---|---|---|---|
Germany
100.0
%
| 56 | 100.0 % | 37 | 100.0 % | -33.67% |
Managers
| Managers | Title | Age | Since |
|---|---|---|---|
| Chief Executive Officer | 56 | - | |
| Director of Finance/CFO | - | 01/22/01 | |
Olaf Randerath
CTO | Chief Tech/Sci/R&D Officer | - | - |
Sven Pauly
IRC | Investor Relations Contact | - | - |
Sanjeev Gotru
PRN | Corporate Officer/Principal | - | - |
Susanne Endreß
LAW | General Counsel | - | - |
Harald Weyand
SAM | Sales & Marketing | - | - |
Matthias Wendl
SAM | Sales & Marketing | - | - |
Thomas Milz
PRN | Corporate Officer/Principal | 59 | 01/21/01 |
Susanne Böhme
HRO | Human Resources Officer | - | - |
Members of the board
| Members of the board | Title | Age | Since |
|---|---|---|---|
Edin Hadzic
BRD | Director/Board Member | 53 | 01/21/01 |
Olaf Elbracht
BRD | Director/Board Member | 59 | 01/21/01 |
| Chairman | 51 | 01/21/01 | |
| Director/Board Member | 39 | 01/21/01 | |
| Director/Board Member | - | 01/22/01 |
Share class
| Vote | Quantity | Free-Float | Company-owned shares | Total Float | |
|---|---|---|---|---|---|
| Stock A | 1 | 8,500,000 | 8,330,000 ( 98.00 %) | 170,000 ( 2.000 %) | 98.00 % |
Company contact information
APONTIS PHARMA AG
Alfred-Nobel-Strasse 10
40789, Monheim am Rhein
+49 2173 8955 4949
https://www.apontis-pharma.de
Sector
Sales per Business
Trading Rating
Investor Rating
ESG Refinitiv
Sell
Buy
Mean consensus
BUY
Number of Analysts
4
Last Close Price
8.54
EUR
Average target price
17.38
EUR
Spread / Average Target
+103.45%
EPS Revisions
Quarterly revenue - Rate of surprise
| 1st Jan change | Capi. | |
|---|---|---|
| +78.95% | 76.14M | |
| +55.02% | 815B | |
| +44.25% | 654B | |
| -6.14% | 354B | |
| +21.38% | 337B | |
| +11.13% | 302B | |
| +18.45% | 247B | |
| +2.09% | 229B | |
| +13.03% | 219B | |
| +8.88% | 171B |
- Stock Market
- Equities
- APPH Stock
- Company Apontis Pharma AG
